Brokerages Anticipate Teleflex Incorporated (TFX) to Post $1.89 Earnings Per Share
Analysts expect Teleflex Incorporated (NYSE:TFX) to announce earnings of $1.89 per share for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Teleflex’s earnings. The lowest EPS estimate is $1.82 and the highest is $1.92. Teleflex also reported earnings per share of $1.89 during the same quarter last year. The business is scheduled to issue its next earnings results on Thursday, July 27th.
On average, analysts expect that Teleflex will report full-year earnings of $8.16 per share for the current fiscal year, with EPS estimates ranging from $8.11 to $8.22. For the next financial year, analysts anticipate that the company will report earnings of $9.48 per share, with EPS estimates ranging from $9.34 to $9.77. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Teleflex.
Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, May 4th. The medical technology company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.69 by $0.11. Teleflex had a return on equity of 16.17% and a net margin of 11.75%. The business had revenue of $487.90 million during the quarter, compared to analysts’ expectations of $472.81 million. During the same quarter last year, the business posted $1.52 earnings per share. The business’s revenue for the quarter was up 14.8% on a year-over-year basis.
Several research firms recently weighed in on TFX. Jefferies Group LLC set a $205.00 price target on Teleflex and gave the company a “buy” rating in a research report on Saturday, March 25th. Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a research report on Saturday, May 20th. Leerink Swann upped their price target on Teleflex from $215.00 to $220.00 and gave the company a “market perform” rating in a research report on Friday, June 9th. Needham & Company LLC began coverage on Teleflex in a research report on Monday, March 6th. They set a “buy” rating and a $221.00 price target on the stock. Finally, Deutsche Bank AG upped their price target on Teleflex from $213.00 to $220.00 and gave the company a “buy” rating in a research report on Monday, May 8th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $216.17.
In other Teleflex news, Director Stephen K. M.D. Klasko sold 5,200 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $193.56, for a total value of $1,006,512.00. Following the transaction, the director now directly owns 12,880 shares of the company’s stock, valued at approximately $2,493,052.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Stuart A. Randle sold 2,500 shares of the company’s stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $205.67, for a total value of $514,175.00. Following the completion of the transaction, the director now directly owns 7,532 shares in the company, valued at $1,549,106.44. The disclosure for this sale can be found here. Insiders have sold 10,146 shares of company stock worth $1,996,554 over the last three months. 2.39% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Pennsylvania Trust Co raised its position in shares of Teleflex by 0.7% in the first quarter. Pennsylvania Trust Co now owns 2,165 shares of the medical technology company’s stock valued at $419,000 after buying an additional 15 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its position in shares of Teleflex by 3.1% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,175 shares of the medical technology company’s stock valued at $213,000 after buying an additional 35 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Teleflex by 0.6% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,553 shares of the medical technology company’s stock valued at $1,270,000 after buying an additional 37 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Teleflex by 0.6% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,560 shares of the medical technology company’s stock valued at $1,271,000 after buying an additional 38 shares during the last quarter. Finally, Brown Advisory Inc. raised its position in shares of Teleflex by 1.7% in the fourth quarter. Brown Advisory Inc. now owns 3,397 shares of the medical technology company’s stock valued at $547,000 after buying an additional 57 shares during the last quarter. 93.33% of the stock is currently owned by institutional investors.
Shares of Teleflex (NYSE TFX) traded up 1.03% on Monday, hitting $202.90. The stock had a trading volume of 41,710 shares. The company’s 50-day moving average price is $200.57 and its 200 day moving average price is $183.63. The firm has a market cap of $9.13 billion, a P/E ratio of 42.11 and a beta of 1.05. Teleflex has a 12-month low of $136.53 and a 12-month high of $211.21.
The firm also recently declared a quarterly dividend, which was paid on Thursday, June 15th. Investors of record on Monday, May 15th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend was Thursday, May 11th. Teleflex’s payout ratio is 28.22%.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.